Jaba Recordati
↗Porto Salvo, Portugal
Jaba Recordati is the Portuguese subsidiary of the international pharmaceutical group Recordati S.p.A. Founded in 1927 as JABA and acquired by Recordati in 2006, the company focuses on the marketing and sale of pharmaceutical products across several therapeutic areas, including cardiovascular, urological, gastrointestinal, and pain control, as well as consumer healthcare/OTC products.
As part of the Recordati Group, the company benefits from a global R&D and manufacturing network while maintaining a strong local presence in Portugal and expanding into PALOP countries (Portuguese-speaking African countries). The company emphasizes ethical rigor, innovation, and a patient-centric approach to healthcare.
CLASSIFICATION
Company Type:Pharma
Therapeutic Areas:
Industry:Pharmaceuticals
Sub-Industry:Specialty & Primary Care, Rare Diseases
SIZE & FINANCIALS
Employees:201-500
Founded:1927
Ownership:subsidiary
Status:operating
STOCK
Exchange:Borsa Italiana (Parent Company: REC.MI)
Ticker:REC
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial
Modalities:Small molecule
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Parent Company:Recordati S.p.A.
Acquired By:Recordati S.p.A. (2006-01-01)
Key Partnerships:GSK (Distribution rights for Avodart and Combodart/Duodart), Kissei (Silodosin/Urorec)
COMPETITION
Position:Leader
Competitors:Tecnimede Group, Bial, Servier Portugal, Angelini Portugal
LEADERSHIP
Key Executives:
Nelson Pires - General Manager
LINKS
Website:jaba-recordati.pt
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Jaba Recordati and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Jaba Recordati. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.